At the J.P. Morgan Healthcare Conference in January 2027, 3DHEALS and Biotools Innovator will co-host an exclusive reception tailored specifically for founders and investors in the biotools sector. While JPM Week traditionally prioritizes therapeutics, this evening offers a dedicated space for the companies building the instruments, platforms, and enabling technologies that power modern biopharma and life science research and development. The gathering is primarily invitation-only for selected founders, investors, and strategic partners, with a limited number of general reception tickets available to the broader biotools community. Designed to foster high-value networking, the event will center on the future of biotools innovation, including but not limited to lab automation, 3D bioprinting, advanced manufacturing, and data-driven discovery.

Stay tuned for the announcement of an exciting in-person event on Jan 10th, 2027.

Subscribe here to get updates.

The post 3HEALS & BioTools Innovator At JPM 2027 🗓 appeared first on 3DHeals.

Apply to speak or sponsor the event: info@3dheals.com
Subscribe here to receive event emails.

The post Post-Processing : The Last Piece of Puzzle? 🗓 appeared first on 3DHeals.

Apply to speak or sponsor the event: info@3dheals.com
Subscribe here to receive event emails.

Speakers:

Jade Ward

Jade is the Research Development Specialist for the AMPrint Center at the Rochester Institute of Technology. Holding a PhD in Mechanical and Industrial Engineering, her work centers on enhancing prosthetic and orthotic device design using additive technologies, and she has instructed several courses in the field. As a passionate changemaker, Jade received the Bruce R. James Distinguished Public Service Award for her non-profit initiatives to increase access to low-cost 3D-printed upper limb prostheses in low-resource areas. And now, Jade is driving the Center’s engagement with the latest bioprinting innovations in healthcare, integrating technology with biology toward transformative real-world impact.

Tergel Bayarsaikhan

Tergel Bayarsaikhan is the founder and CEO of Rightfit, a Mongolia-based medtech company building an AI-assisted orthotic design platform with outcome tracking, optimized for 3D printing. Rightfit enables clinicians to design patient-specific ankle foot orthoses and print them locally on desktop printers, bringing custom orthotics to patients in a country with no formal prosthetics and orthotics profession.

He holds an MSc in Architectural Engineering from Budapest University of Technology and Economics, where he researched 3D printing with recycled materials. His first medical 3D print was a grip to help his grandmother hold a kitchen knife, which set him on the path to founding Rightfit in 2023.

The post Next-Gen 3D Printed Orthotics and Prosthetics 🗓 appeared first on 3DHeals.

The defining shift of 2026 is from printing structure to printing function, and from lab-stage novelty toward standardized, regulator-legible material systems. Biomaterials is moving from a printable-hydrogel or metal powder afterthought to the regulated, functional, investment-grade core of 3D-printed medicine across soft (function-first bioresins), hard (ion-releasing ceramics and bioactive glass), and structural (titanium and titanium-tantalum lattices) tracks at once. Biomaterials Frontier convenes the researchers, founders, and industry leaders defining that shift.

Subscribe here to receive event emails.

Apply to speak or sponsor the event: info@3dheals.com

Speakers:

Scott Taylor, PhD

Dr. Scott Taylor is Director of Product Engineering at Poly-Med and specializes in material selection and medical device design. He has worked on development teams for more than twenty marketed medical devices and is experienced in the creation of novel materials and processes, product design and development, advanced manufacturing services, application and development of intellectual property, as well as physical and chemical testing protocols.

His 10-year involvement with ASTM includes the development and maintenance of standards within committees F04 (Medical and Surgical Materials and Devices) and F42 (Additive Manufacturing Technologies), including chairing the joint group for absorbable polymeric materials and test methods.

Dr. Taylor has undergraduate degrees in physics and mechanical engineering from Furman University and Clemson University, respectively, and completed his doctorate in Bioengineering from Clemson University. Through his tenure, Dr. Taylor has published numerous papers and conference abstracts, several book chapters, and is inventor for more than 25 US and international patents. In addition to his position at Poly-Med, he maintains an appointment as adjunct faculty of Bioengineering at Clemson University.

Fabian Trumper

Fabian Trumper is the Co-Founder and CEO of Arrakis Bio, an Israeli biotech company revolutionizing the field of regenerative human biomaterials with its True Human Collagen™, the best biomaterial for regenerative medical and aesthetics applications, bio-manufactured using cultivated human dermal fibroblasts in an industrially scalable process. He is a 3X founder, with over two decades of product, technology, and business leadership across deep tech and life sciences, including as VP of Products and Co-Founder at LightBits Labs and CEO and Co-Founder at Bountica. Fabian holds an MBA in Marketing Strategy from INSEAD.

Prof. Kamal Choudhary

Kamal Choudhary is an Assistant Professor in the Department of Materials Science and Engineering, with a joint appointment in Electrical and Computer Engineering at Johns Hopkins University. He is an elected fellow of the American Physical Society. His research focuses on atomistic materials design using classical mechanics, quantum mechanics, and machine learning methods to accelerate experimental discovery. He earned his Ph.D. in Materials Science and Engineering from the University of Florida in 2015 and previously served as a Staff Scientist at the National Institute of Standards and Technology (NIST). He is the creator of the widely used JARVIS , AtomGPT.org and the ChatGPT Material Explorer infrastructures for materials design with over 200000 users wordlwide. He has published over 100 peer-reviewed articles, with over 10000 citations. He serves as an associate editor for Nature: npj Computational Materials, and is an editorial board member of Materials Today Communications, PRX Energy, and Machine Learning: Science and Technology journals.

Andrew C. Weems

Resilient founder and CEO Dr Andrew Weems (PhD) is a former assistant professor at Ohio University specializing in medical devices, degradable polymers, photopolymers, and biomedical engineering. He is a senior member of the National Academy of Inventors, he previously founded the UK company 4D Medicine Ltd, developing photopolymer resins, and he has worked on Class 1, 2 and 3 medical devices. At Resilient Medical, Weems has multiple patents related to tissue scaffolding devices and has led the commercialization efforts of the Bravo device platform, including regulatory strategy development, fundraising, and product development.

Ebrahim Yarali

Ebrahim Yarali is a postdoctoral researcher at the Institute for Technology-Inspired Regenerative Medicine (MERLN), Maastricht University. His multi-disciplinary research focuses on developing acoustic-responsive 3D architected biomaterials that promote skeletal regeneration by guiding both chondrogenic and osteogenic differentiation of stem cells. By integrating advanced mechanical modeling, acoustic wave stimulation, and cutting-edge biofabrication techniques, he aims to address major healthcare challenges, particularly osteoarthritis as one of the most common musculoskeletal diseases.

He earned his PhD from the Departments of Biomechanical Engineering and Precision and Microsystems Engineering at Delft University of Technology (TU Delft) and holds M.Sc. and B.Sc. degrees in Mechanical Engineering. His prior work has focused on the mechanobiology of bone-cell-laden architected biomaterials, stimuli-responsive (smart) materials, 4D printing, and micro-additive manufacturing. With around 20 peer-reviewed publications in leading journals, such as Nature Communications and Advanced Materials, he aims to translate stimuli-responsive architected biomaterials into clinical applications through multidisciplinary approaches that advance tissue engineering.

Moderator:

Craig Rosenblum

Craig Rosenblum is President of Himed, LLC, a global leader in calcium phosphate biomaterials with over 35 years of innovation in plasma spray coatings and surface treatments for medical and dental devices. He collaborates with manufacturers worldwide to deliver advanced biomaterial solutions and has led interdisciplinary teams to drive the company’s growth and industry leadership. Craig discovered a unique application for post-processing of additively manufactured medical devices using Himed’s proprietary and biocompatible resorbable blast media. Himed has established the Bioceramics Center of ExcellenceTM to develop new bioceramic bioinks and rapid prototyping of next-generation medical implant designs.

Craig holds both a BS and MS in Materials Science & Engineering (Biomaterials) from The Johns Hopkins University. His groundbreaking research explored the variations in the microstructure and mechanical properties of dental enamel, first demonstrating its unique heterogeneous nature. Craig remains active with Johns Hopkins as a member of the Materials Science & Engineering Advisory Committee.

Event Sponsors:

The post Biomaterials Frontier for Medical 3D Printing 🗓 appeared first on 3DHeals.

New Approach Methodologies (NAMs) are redefining how preclinical safety and efficacy are evaluated by shifting away from traditional animal models toward human-relevant, technology-driven approaches such as complex in vitro systems, 3D organoids, organs-on-chips, and in silico modeling. These methods aim to improve the predictive power of human responses, reduce development time and cost, and minimize the ethical and scientific limitations of animal testing, aligning with broader efforts across the life sciences to modernize drug development. NAMs are increasingly central in conversations about AI-enhanced 3D models, microphysiological systems, and data-rich platforms that can better capture human biology at the preclinical stage.[fda] In the United States, recent FDA policy initiatives have begun to operationalize this vision by providing a formal validation and regulatory framework for NAMs in preclinical drug development. In March 2026, the FDA released draft guidance, “General Considerations for the Use of New Approach Methodologies in Drug Development,” outlining principles for human biological relevance, technical characterization, and fit-for-purpose use of NAMs in nonclinical safety packages submitted with INDs. Complementary actions under broader modernization efforts, such as Operation TrialBlazer, explicitly encourage the use of NAMs—including AI-powered models and organ-on-chip systems—as alternatives to animal toxicology for dose selection and safety assessment, signaling that regulators now expect sponsors to consider NAMs when they can improve human predictivity and support safer, faster translation to first-in-human trials.[fda] In this upcoming virtual event, our panelists will focus on the latest technical development, industry adoption, and regulatory landscape surrounding approaches using biofabrication and microfluidics-focused platforms.

Apply to speak or sponsor the event: info@3dheals.com

Subscribe here to receive event emails.

Speakers:

Andrew Lee

Andrew is the co-founder and senior scientist at FluidForm Bio, a team based in Boston looking to develop a cure to diabetes. Broadly, Andrew’s interests are in building functionally accurate and sophisticated human tissues that can one day be utilized in a repair, regeneration, and replacement.

Graham Craig

Graham Craig is Chief Commercial Officer at VoxCell, a Canadian biotechnology company developing high-resolution, vascularized 3D tissue models as New Approach Methodologies (NAMs) for drug development. He leads VoxCell’s commercial strategy, global business development, and strategic partnerships, working to put more human-relevant preclinical models into the hands of pharmaceutical companies, CROs, and research institutions, so teams can generate decision-enabling data earlier and reduce reliance on traditional animal testing.

Graham brings more than 18 years of experience in commercialization and strategic partnerships across the pharmaceutical and biotech sectors. Before joining VoxCell he was Director of Corporate Development at AbCellera and held senior roles at STEMCELL Technologies. Earlier in his career he spent seven years as a commercial strategy consultant at IQVIA, advising pharmaceutical companies across Europe, Asia, and North America.

Pranav Joshi

Dr. Pranav Joshi is a translational biomedical scientist and Senior Scientist at Bioprinting Laboratories Inc., where he leads the development and validation of human-relevant 3D cell and organoid platforms for predictive toxicology, drug discovery, and new approach methodologies (NAMs). His work integrates human iPSC-derived brain and liver organoids, microarray 3D bioprinting, dynamic perfusion culture, high-content imaging, and scalable assay development to improve the reproducibility and translational relevance of preclinical testing. He has served as principal investigator on multiple NIH SBIR/STTR projects focused on gene-edited liver organoids, engineered brain organoids for developmental neurotoxicity testing, and pillar/perfusion plate systems for scalable organoid culture.

At Bioprinting Laboratories, Dr. Joshi has played a central role in translating organoid and microphysiological system technologies from research concepts into commercially deployable platforms for high-throughput screening. His recent work focuses on the scale-up, quality control, cryopreservation, and assay-ready deployment of human organoids for toxicology and drug screening. He also served as technical lead for an NIH I-Corps program focused on understanding barriers to adoption of advanced human-relevant models, and his team’s “Human Brain Organoids to Predict DNT” project was selected as a Phase 1 winner of the NIH Complement-ARIE NAMs Reduction to Practice Challenge. His broader research interests include developmental neurotoxicity, metabolism-mediated toxicity, organoid standardization, and the validation of fit-for-purpose NAMs for academic, industrial, and regulatory applications.

Mike Clements

Dr. Mike Clements is Senior Vice President for Scientific Partnerships and Strategy at Axion BioSystems, where he focuses on advancing the use of human stem cell-derived models and functional cell-based assays in drug discovery and toxicology. He earned his PhD in neuropharmacology from the University of Oxford and completed postdoctoral training in the UK and US.

In 2014, Dr. Clements published the first study using the Maestro multielectrode array (MEA) system with stem cell-derived cardiomyocytes, helping demonstrate their potential as predictive tools for preclinical cardiac safety assessment and contributing to work that informed the Comprehensive in Vitro Proarrhythmia Assay (CiPA) initiative. He was also editor of Stem Cell-Derived Models in Toxicology and previously served as President of the Society of Toxicology’s Stem Cells Specialty Section. More recently, he has been involved in Axion BioSystems’ effort to advance its human iPSC-cardiomyocyte MEA assay through the FDA’s ISTAND program, providing a practical example of the journey from an emerging human-relevant model toward a standardized, regulatory-ready New Approach Methodology (NAM).

Alexandre CIVIERE

Biomedical engineer with an MBA and over ten years in biotechnology at the interface of cell technology and medical devices, spanning pre-clinical and clinical R&D for innovative therapies. As Sales & Business Manager at REVIVO BioSystems in Singapore, he works with pharmaceutical and cosmetic companies on human skin models and barrier tissues for safety and efficacy studies.

Moderator:

Lowry Curley

Lowry Curley is a scientist-entrepreneur and developer of foundational neural microphysiological systems (MPS) technology that became the core platform of the first company he founded, AxoSim, which is now 28bio. He took AxoSim from a Tulane University spinout to a venture-backed company that counted nearly every top 25 global pharma company as a customer, translating early-stage research into a validated, human-relevant platform for neurological drug discovery. As founder and CEO, he built a product pipeline on IP licensed from Johns Hopkins, UC San Diego, and Tulane, and led two acquisitions to expand the platform.

He now runs Luna LifeSci, an advisory firm helping pharmaceutical and biotech companies adopt New Approach Methodologies (NAMs) in their preclinical programs, as well as helping life science founders and startups accelerate their commercialization, company building, and fundraising strategies.

The post New Approach Methodologies: From Theory to Validation 🗓 appeared first on 3DHeals.

Bench to Bedside: Bioprinting Innovations brings together an exceptional lineup of pioneers spanning the full translational journey of 3D bioprinting — from novel absorbable biomaterials and clinical-grade bone implants to physiologically relevant in vitro models and next-generation drug discovery platforms. This event arrives at a pivotal moment for the field. The global 3D bioprinting market was valued at $2.3 billion in 2024 and is projected to grow at a CAGR of 15.1%, reaching an estimated $5.4 billion by 2030 (Ref 1), driven by advances in biomaterials, stem cell research, and rising adoption across pharmaceutical and clinical applications. Bioprinted tissue models alone are projected to drive $1.5 billion in drug testing market value by 2028 (Ref 1), while orthopedic implants are expected to capture 33.9% of bioprinting revenue in 2025 (Ref 2) — precisely the intersecting domains our speakers represent. This panel covers every critical layer of the bioprinting ecosystem: the polymer chemistry that makes implants possible, the printing technology that gives them form, the commercial and regulatory strategy that brings them to patients, and the in vitro models that are reshaping how drugs are developed. Whether you are a researcher, clinician, entrepreneur, or investor, this is a conversation you cannot afford to miss.

Apply to speak or sponsor the event: info@3dheals.com

Subscribe here to receive event emails.

Rao S. Bezwada

An accomplished scientist and entrepreneur, Rao S. Bezwada, Ph.D. established Bezwada Biomedical, an innovation-based and technology-driven research company, in 2003. The company is focused on developing a wide range of novel absorbable polymeric biomaterials to enhance quality of life by producing next generation bioabsorbable medical devices with therapeutic applications. Dr. Bezwada earned a doctorate in chemistry from the Stevens Institute of Technology in New Jersey and has over 40 years of research experience in the medical device industry, including 20 years of service at Ethicon, Inc. (a Johnson & Johnson Company). While at Ethicon, Dr. Bezwada’s research and development efforts led to the launch of a number of products, including Monocryl®, a new ultra-pliable synthetic absorbable monofilament suture. This product has represented worldwide sales of more than two (2) billion dollars since its launch in 1993 and current annual sales of over 100 million dollars. The development of Monocryl, is a testament to Dr Bezwada’s innovative prowess. Not only has this product significantly impacted medical practices worldwide, but its success also earned him the prestigious Johnson medal from Johnson and Johnson in 1996. His prolific inventiveness, as evidenced by over 150 issued US patents on absorbable polyurethanes, absorbable amino acid polymers, absorbable polyester amides, absorbable polyoxaesters, and controlled release polymers, underscores his dedication to pushing the boundaries of biomedical technology. Dr Bezwada’s leadership and guidance has led to the creation of more than 10 FDA-approved products including MONTAGE® Putty, MONTAGE Fast Set Putty, Montage Flowable Putty, and PERMATAGE Putty, marketed by Abyrx for wound healing and bone applications, all based on Bezwada Biomedical’s absorbable polyurethane technology.

Neeti Srivastava

Dr. Neeti Srivastava has been a key member of Bezwada Biomedical since 2009, bringing over 15 years of experience in biomedical research and a Ph.D. in Biochemistry. With deep expertise in absorbable polymers, drug delivery systems, biomaterials, and quality management systems, Dr. Srivastava leads research and development, business development, and quality assurance, always focusing on creating innovative, safe, and effective solutions to improve patient care.

Dr. Srivastava has extensive knowledge of Bezwada’s absorbable polyurethane technology, including bio-based polyurethanes, and holds patents on the technology, solidifying her position as a leader in polymer science. Her contributions were essential in the creation of TissuBond™, a tissue adhesive that secured NSF SBIR Phase I and II grants. She also worked on absorbable polyurethane formulations for a bone hemostat product that received 510(k) approval from the FDA and was commercialized as MONTAGE® by Abyrx, Inc.

Her leadership and dedicated efforts were instrumental in Bezwada Biomedical’s achievement of ISO 9001 and ISO 13485 certifications. Through her guidance in building a robust quality management system, she has ensured the company’s commitment to delivering safe and effective polymers that meet the highest regulatory standards.

Dr. Srivastava is also an established voice in the scientific community, having authored multiple scholarly articles and presented her research at esteemed conferences such as the American Chemical Society and the Society for Biomaterials. Her work continues to drive both academic and industrial advancements in biomedical science and drug delivery technologies.

Monica Wellejus

Monica Wellejus is a technology commercialization strategist who has spent almost seven years working at the intersection of biomaterials and medical 3D printing. With an MA in Business, Language, and Culture, Monica entered the field from a non-technical angle but quickly became involved in all aspects of bringing bone regenerative solutions to market, from product development and quality control to regulatory pathways, evidence generation, and global commercialization strategies. She has been part of Ossiform® since 2019, where she manages the company’s commercial and go-to-market activities as the Chief Commercial Officer.

Ossiform® develops bio-integrative bone substitutes with tailored structural properties to improve bone healing outcomes, simplify complex procedures, and reduce complication rates in orthopedics and spine. Its novel 3D printing technology is further used to provide bone-mimicking 3D cell culture systems for improving the physiological relevance of in vitro models in bone and cancer research.

Carlos Ezio

Carlos Ezio is the CEO and co-founder of Criocore, where his work focuses on developing physiologically relevant in vitro models for more predictive drug development. Previously, he spent six years in the Shrike Zhang Lab at Harvard Medical School, where he contributed to more than 30 scientific publications, several patents, and the development of novel technologies. His research focused on biofabrication technologies, including 3D bioprinting, organ-on-chip platforms, and biomedical devices for engineering complex tissue models. Carlos was recognized as an MIT Innovators 35 Under 35 LATAM honoree, a Founder in Residence at Antler, and part of the inaugural cohort of MassVentures’ Founders School.

Joanna Xylas, PhD

Joanna Xylas, PhD, is a biomedical engineer and entrepreneur working at the intersection of biomaterials, manufacturing, and clinical translation. She is a Cofounder and CEO of Materialize Bio, an NSF-backed, Tufts University spinout developing high-performance implants from natural biopolymers using its proprietary GLEN 3D™ manufacturing platform.

Her career has focused on advancing novel technologies into human use. She has led clinical and commercialization strategy for implantable and bio-integrative platforms at companies including Brixton Biosciences and TISSIUM, contributing to the translation of first-in-class, 3D-printed and biosynthetic implants into first-in-human studies.

Through this work, Dr. Xylas has built deep experience bridging engineering, biology, and surgery by partnering with surgeons, shaping clinical strategy, and driving adoption of emerging technologies. She holds a PhD in Biomedical Engineering from Tufts University and is committed to bringing forward technologies that meaningfully improve patient care.

Moderator:

Dr. Jenny Chen

Dr. Jenny Chen is trained as a neuroradiologist, and founder/CEO of 3DHEALS. Her main interests include next-generation education, 3D printing in the healthcare sector, automated biology, and artificial intelligence. She is an angel investor who invests in Pitch3D companies.

The post Bench to Bedside: Bioprinting Innovations 🗓 appeared first on 3DHeals.

Physical AI in Medicine is where intelligent algorithms stop living only in the cloud and begin to shape tangible, patient-specific solutions through 3D technologies and 3D printing. This event will explore how AI-driven workflows are transforming the healthcare industry for the 3DHEALS audience. While the potential impact of “physical AI” could be pervasive and profound, this event focuses on its impact on existing or new 3D technologies in medtech and biotech, such as optimized 3D printing workflow in medicine and dentistry, surgical robots, and even biofabrication. You will unlikely to find another event similar to this one despite the popularity of “physical AI”.

Apply to speak or sponsor the event: info@3dheals.com

Subscribe here to receive event emails.

The post Physical AI in Medicine 🗓 appeared first on 3DHeals.

3D surgical planning is undergoing rapid transformation, converging physical and digital tools into precision-first clinical workflows. The surgical planning software market is projected to surge from $12 billion in 2025 to over $71 billion by 2035, driven by AI integration, personalized medicine, and advanced imaging. Point-of-care manufacturing, AI-driven DICOM segmentation, and solution-as-a-service models are among the most disruptive emerging trends. Orthopedic surgery commands the largest market share at 41.8%, with Stryker, Siemens Healthineers, Brainlab, Materialise, and GE Healthcare among the dominant players. In December 2025, Axial3D received FDA clearance for AI tools that significantly reduce scan-to-model design time — a signal of accelerating regulatory momentum. Risks remain real: reimbursement pathways for patient-specific tools are uneven, regulatory clearance timelines are long, and clinical validation data lag commercial adoption. Interoperability among imaging systems, planning software, and manufacturing workflows remains inconsistent across institutions. Attend this rare event with global experts to understand where the clinical, regulatory, and technological edges meet — and how innovators like those building patient-specific implant systems are solving problems that generic tools simply cannot.

Subscribe here to receive event emails.

Speakers:

Tim Van Cleynenbreugel

Tim Van Cleynenbreugel is co-Founder and CTO of Replasia, a Belgian medical device startup focused on hip preservation in young adults. With a PhD in Engineering from KU Leuven and a background spanning polymer and metal additive manufacturing at Materialise Dental and LayerWise, and medical product development and business development at Comate Engineering & Design, Tim brings over two decades of experience at the intersection of engineering, medical imaging, and device development.
At Replasia, he leads the development of HipStudio, a CT-based 3D analysis platform covering both hip dysplasia (DDH) and femoroacetabular impingement (FAI), and the 3D-Shelf System, a patient-specific 3D-printed titanium implant for DDH treatment.

Beatriz Dominguez Gonzalez

Beatriz Dominguez Gonzalez is the Global Market Manager for software in hospitals and universities at Materialise, where she leads global market strategies for 3D planning and printing. Her role involves driving innovation and forging strategic alliances with key opinion leaders to increase the adoption of 3D technologies in hospitals and universities. Beatriz is also a founder member of the EU 3D SIG and a passionate advocate for scientific communities.

Mark Tan

Dr Mark Tan is a Radiologist and the Clinical Lead of the Singapore General Hospital 3D Printing Centre. Dr Tan enjoys working with clinical teams on virtual surgical planning for head and neck, plastic and reconstructive, orthopaedic and cardiac surgeries. Dr Tan also enjoys working with clinical teams, imagers, engineers, administrators, academia and industry on designing and producing from medical imaging, in-house and external to the healthcare facility, patient-specific 3D printed modes of communication for medical imaging as well as medical devices. These include anatomical models for surgical rehearsal and implant sizing, surgical guides for localisation and reconstruction, bespoke orthotics and prosthetics, as well as custom implants, to improve clinical care.

Rashi Gupta

As a Biomedical Engineer, Rashi specializes in patient-specific surgical planning, custom implant design, and 3D printing applications in orthopedics, craniofacial reconstruction, and medical education.
She has over six years of experience in the field, having worked at Imaginarium, one of India’s leading 3D printing companies, where she collaborated with surgeons on complex osteotomies, deformity corrections, and reconstructive procedures. Her expertise spans CT/MRI image segmentation, CAD modeling, surgical guide fabrication, and virtual surgical planning.

Currently based in St. Louis, MO, Rashi is working as a 3D printing Engineer at SSM Health Cardinal Glennon Children’s hospital, collaborating with doctors and researchers at Saint Louis University (SLU) and WashU, BJC HealthCare to help inculcate and integrate 3D printing technology into clinical practice.

Highlights of Work:
Designed and developed more than 400 patient-specific surgical guides and anatomical models that reduced surgical time and improved accuracy.
Supported surgeries across orthopedics, craniofacial, and maxillofacial specialties.

Lectures & Training:
Delivered more than 30 workshops and talks on 3D printing in medicine for medical professionals and students in India and internationally.

David B. Pearlstone, MD

Dr. Pearlstone is a founder/principal and CEO of DICOM Director. LLC, as well as a founder and principal at Voxelary Research, Inc. Prior to that, Dr. Pearlstone had a long career in academic medicine, previously serving as Medical Director for Vitas Healthcare of Connecticut, Assistant Professor of Surgery at Yale School of Medicine, Director of Breast Services at Hackensack University Medical Center, and Associate Chairman of Surgery, Chief of Surgical Oncology, and Director of Surgical Research at Lincoln Hospital in New York City.

Dr. Pearlstone has worked in biomedical technology transfer since 2002, serving on the faculty of Clemson University College of Engineering in Clemson, SC, and the Stevens Institute of Technology in Hoboken, NJ. In 2010, Dr. Pearlstone received his MBA from the Leadership in Healthcare program at the Yale University School of Management.

Moderator:

Dr. Jenny Chen

Dr. Jenny Chen is trained as a neuroradiologist, and founder/CEO of 3DHEALS. Her main interests include next-generation education, 3D printing in the healthcare sector, automated biology, and artificial intelligence. She is an angel investor who invests in Pitch3D companies.

Thanks to our sponsor:

The post Advancing 3D Surgical Planning 🗓 appeared first on 3DHeals.

Why this event? Because future healthcare will be more personalized, 3D data-driven, and digitally fabricated (e.g., 3D printing and bioprinting). Life in 3D is the only niche-focused event that unites the most transformative next-gen medical devices, therapeutics, and biotools under one cohesive investment lens, including but not limited to —cell therapy, biofabrication, frontier medical devices, and drug discovery. If you are ready for a mindset shift, this is the event for you.

Since 2018, 3DHEALS has hosted more than 100 early-stage startups in the 3D medtech and biotech space to raise funds and receive advisory through its Pitch3D program. This year, the company is organizing its first dedicated in-person event for investors and entrepreneurs in this space. The event will take place the night before the official 2026 JP Morgan Healthcare Conference in the beautiful downtown San Francisco office of K&L Gates, California, USA. The goal is to host investors and founders who share a maniacal belief that the 3D mindset will enable the next wave of biomedical innovations.

While this event is mostly by invitation only (for Example, Pitch3D founders), related parties can purchase a limited number of tickets. The event is capped at 150 attendees. To qualify as an investor, you must demonstrate that you are an accredited investor or belong to a relevant investment institution. To qualify for media tickets, you must provide relevant LinkedIn or website credentials to be admitted.

Tentative Agenda:

4:00-4:20 PM Registration/Network

4:20-4:25 PM K&L Gates 3DHEALS Intro

4:25-4:40 PM Keynote Speaker-Mike Cordonnier, CEO, Carlsmed (IPO 2025)

4:40 – 5:40 PM Investor Panel

5:40-6:20 PM Startup Panel 1

6:20-6:30 PM Break

6:30-7:10 PM Startup Panel 2

7:10 – 8:00 PM Networking/Wrap up

4:00 -8:00 Poster Session

Keynote Speaker:

Mike Cordonnier

Mike Cordonnier is the Co-Founder, President and Chief Executive Officer at Carlsmed, and serves as the Chair of the Board of Directors.

With more than two decades of leadership experience introducing groundbreaking medical technologies, Mike has guided teams across both private and public organizations, including NuVasive, Ellipse Technologies, Zimmer Biomet, Orchid Orthopedics, and X-Spine Systems. He holds a Bachelor of Science degree in Mechanical Engineering from the University of Dayton.

Speakers:

Iris Wedeking

Iris Wedeking, MBA, is the CEO and Founder of iDentical, a dental technology company that is revolutionizing tooth replacement with the world’s first drill-free, personalized, 3D-printed dental implants. Mrs. Wedeking has been a visionary leader in the dental industry for 10 years. Prior to founding iDentical, she managed the operations for three dental implant centers in the San Francisco Bay Area, where she saw firsthand the challenges of the current paradigm of implant dentistry for both patients and dentists. This experience inspired her to found iDentical, Inc. to develop and commercialize a drill-free dental implant solution that addresses the drawbacks of traditional dental implants.

Mrs. Wedeking is a two-time founder and CEO. Previously, she founded and scaled a national organization in the oncology sector (Kesem) that is now in its 25th year of operation with 115 chapters across 41 states. She also served as a senior marketing research leader at The Clorox Company. Iris holds an MBA from UC Berkeley’s Haas School of Business and a BA, summa cum laude, from Tufts University. She resides in Walnut Creek, California, with her husband (a dentist) and three children.

Jessica Miller

Jessica Miller is the founder of RocketBio and invests with a long-term, patient-focused approach across tissue engineering, regenerative medicine, and next-generation preclinical tools. Her work centres on advancing breakthrough science into practical clinical and commercial impact.

She serves on the Board of Directors at VoxCell BioInnovation, which develops vascularized 3D-bioprinted tumor models for precision oncology, and is a Director and Strategic Board member at NETRI, a French company creating neuron-based organ-on-chip systems for neurotoxicity, pain, and CNS disease research.

Jessica also supports business development efforts for both companies, forging partnerships across pharma, biotech, and research. With a background in Materials Engineering (University of Toronto) and Nanomaterials (Imperial College London), she brings technical depth and strategic insight to scaling technologies that improve patient outcomes and shape the future of drug development.

Gokce Yildirim

Gilly is a biomedical engineer, inventor, and an operations leader with 20 years of medical device industry and scientific research experience, and currently is the founder and CEO of Vent Creativity Corporation, an AI based digital twin surgical planning and decision-making software serving the orthopaedics and healthcare community.
Gilly started his career in industrial robotic automation, and then translated this knowledge to human biomechanics, design, testing, and regulatory filing of medical devices. Gilly previously advised a multi-billion-dollar industry on product portfolio needs and M&A considerations for multiple $5MM+ NPV projects. He also advised C-level executives for their medical device regulatory and business strategy needs. Gilly has been instrumental in the regulatory testing, documentation, and filing aspects of 13 Class II, 1 IDE, and 1 IND FDA medical device products. Gilly has over 25 peer reviewed published articles in the orthopaedic medical device field. Gilly holds 12 granted patents in the field of big-data driven surgery, additive manufacturing for medical devices, and robotic surgery, and presented foundational research at various peer-reviewed conferences and publications. Gilly holds a Bachelor of Science in Industrial Engineering from NJIT, a Master of Science in Biomedical Engineering and an MBA from Columbia University.

Nikhil S. Joshi

Nikhil Joshi is a Biomedical Engineer with a BS and MS in the field. During undergraduate studies, he was a Research Assistant in Dr. Adam Engler’s lab at UC San Diego, investigating methods to coax stem cells towards various mature cell lineages. Later on, at Columbia University, he served as a Graduate Research Assistant in the lab of Dr. Clark Hung, investigating techniques to enable nutrient delivery to engineered tissue constructs for cartilage cell therapy.

After academia Nikhil has spent 12 years in industry, working as an Engineer and Product Manager on a variety of innovative technologies. Most recently Nikhil was at Auris Health helping to build Monarch, the world’s first robotic endoscopy platform. Nikhil led development of three novel robotic instrumentation devices, from initial concept to design verification testing.

Nikhil has co-invented nine patented technologies, and throughout his career has been driven by the question of how technology can improve healthcare quality.

Karolina Valente

Dr. Karolina Valente is the Founder and CEO of VoxCell, a biotechnology company
advancing 3D bioprinting to develop human-like cancer tissue models and accelerate drug developmnent. With over 12 years of experience in tissue engineering, she holds a Ph.D. in Mechanical Engineering with a focus on bioprinting and drug delivery systems. Under her leadership, VoxCell has grown from 5 to 20 employees and raised over $11M CAD. Her contributions to biotechnology and cancer research have earned her and VoxCell multiple
accolades. In 2023, Douglas Magazine recognized VoxCell as one of its 10 to Watch winners, acknowledging the company’s significant contributions to biotechnology and cancer research. In 2024, Life Sciences BC named VoxCell to its Companies to Watch – Recognition Honour Roll, highlighting its potential and achievements in the life sciences sector. Most recently, The Globe
and Mail’s Report on Business 2025 Changemakers Award recognized Karolina as one of 20 emerging leaders reinventing how business is done in Canada. Passionate about scientific innovation, gender equity, and the future of biotechnology, she continues to drive transformative change in oncology research and 3D bioprinting.

Alyssa Huffman

Alyssa Huffman is an award-winning MedTech entrepreneur, inventor, & thought leader advancing the future of orthopedic & spine care. Orthopedics This Week wrote, “If we were to bet on any young entrepreneur, Alyssa Huffman would be at the top of the list.”

She was the first Commercial Representative appointed to the North American Spine Society (NASS) & has become a respected voice in global spine innovation. Alyssa has presented at the 2025 Congress of Neurological Surgeons Annual Conference, the NASS Biologics Conference, & as both speaker and committee member for the NASS Innovation NetWORK Summit, where she champions evidence-based innovation & commercialization strategy.

In 2009, while working as an Orthopedic/Spine/Biologics Distributor, Alyssa witnessed the devastating complications of failed spine surgery on her diabetic uncle and quadriplegic cousin. This experience inspired the first sketch of what became the A8 INTEGR8™ Porous Pedicle Screw System (the cornerstone of ALLUMIN8’s Therapeutic Hardware™ platform), integrating biomechanical support with regenerative potential to both treat & heal.

Under her leadership, ALLUMIN8 has earned global recognition:
“Best Technology in Spine” Award – Orthopedics This Week
“6 Interesting Orthopedic Startups to Monitor in 2025” – BONEZONE
Global Impact Award 2025 – WashU in St. Louis
$500,000 Awarded – Missouri Technology Corporation
$75,000 Awarded – St. Louis Arch Grants
“Innovators to Watch” – OCCAM Design
“Future Stars of Spine” – Matthew Henshaw
“Top Startups to Watch” – St. Louis Business Journal
“Most Investment Value Award” – MD Inno, Shanghai

Beyond entrepreneurship, Alyssa has contributed to clinical scholarship as co-author of “Innovations in Spine Surgery: A Primer” & “Analgesic Effect of Over-the-Counter Sublingual Magnesium for Trigeminal Neuralgia Management.”

Her two decades of consulting experience span sales, contracting, distribution, marketing, product development, leadership, & team building for MedTech companies across medical devices, biologics, robotics, capital equipment, & pharmaceuticals. Areas of expertise include ortho/spine hardware, regenerative medicine, cardiology, neuro, spine, organ transplant, endovascular therapies, wound healing, temperature management, & stem cell therapies.

Her mission is clear: solve problems for patients, physicians, healthcare organizations, & payors by uniting the healthcare community to create devices, protocols, and techniques that merge rigorous clinical evidence with cost-conscious innovation – accelerating the future of patient care.

Dr. Aadeel Akhtar

Dr. Aadeel Akhtar, CEO and Founder of PSYONIC, started the company after meeting a young girl in Pakistan who was using a tree branch as a prosthetic leg. That moment inspired his mission to create advanced, accessible bionic limbs that restore both function and feeling. PSYONIC’s Ability Hand is the fastest bionic hand on the market, impact-resistant, and the first to provide a sense of touch. It is covered by Medicare and used by humans and robotics companies worldwide, including NASA, Meta, Mercedes, and Google. Dr. Akhtar earned his Ph.D. in Neuroscience and M.S. in Electrical & Computer Engineering from the University of Illinois Urbana-Champaign, and holds a B.S. in Biology and M.S. in Computer Science from Loyola University Chicago. He has been recognized by MIT Technology Review, Newsweek, and secured a three-shark deal on Shark Tank.

Ben Hartkopp

Ben Hartkopp is a seasoned independent researcher, inventor and developer who has been instrumental in co-developing the NovoJet™ Printhead technology since 2016. He is a co-inventor of Quantica’s patent portfolio of printheads, systems and methodologies and currently serves as the Head of Research and IP at Quantica.

Renee Ryan

Renee Ryan is recognized as an industry insider and leading investor, deal-maker, and passionate innovator. She has over 25 years of building category-creating healthcare companies. Renee currently serves as Founder & CEO of PinPrint, a Stanford spin-out focused on optimizing the patient experience for drug and vaccine delivery. She served as CEO and Board member of Cala Health, a pioneer in the field of wearable neuromodulaton therapy having launched two generations of product and consistently doubled revenue each year of her leadership. Previously, she led the medical technology investments for Johnson & Johnson Innovation (JJDC) on the West Coast and Asia Pacific for 8 years. While at J&J, she made over 15 new investments, including the Series A for Cala Health. Other investments include Auris Health, Carbon 3D, Verb Surgical, PowerVision and Tusker Medical, several of which led to significant acquisitions. Previously, she was a healthcare investment banker at Goldman Sachs and Jefferies. She currently sits on the Boards of RefleXion Medical and Neuropace (NPCE).

Mike Graffeo

Mike is the CEO and co-founder of FluidForm Bio, building cures for chronic diseases like type 1 diabetes using 3D bioprinting. In over 25 years in the life sciences, Mike has brought four novel treatments through the FDA that have generated over $20 billion in sales in both startup and growth organizations. Throughout his career, he has worked on the forefront of medicine, translating highly complex treatments and clinical data into successful businesses, in the US and around the world. He is a graduate of Cornell University (B.S. Engineering Physics / Bioengineering, M.Eng. Mechanical Engineering) and Harvard Business School (MBA), where he was a Baker Scholar.

Gurkaran Chowdhry

Gurkaran Chowdhry is a co-founder and the Director of Business Development at 3DBioFibR, where he helps guide the commercial strategy behind the company’s proprietary biomaterials platform. His technical foundation began with graduate research that uncovered key mechanisms behind 3DBioFibR’s fiber formation process, and he is an inventor on the company’s core IP. This mix of scientific depth and business focus allows him to bridge R&D with market needs, support partnership discussions with leading biomedical organizations, and represent the company across industry forums.

In his role, Gurkaran works to align 3DBioFibR’s advanced dry-spinning technology with high-value applications in regenerative medicine, wound care, and surgical materials. The company specializes in manufacturing biopolymer fibers such as collagen, chitosan, and spider silk at a scale far beyond traditional wetspinning or electrospinning methods, enabling the creation of tunable 2D and 3D scaffolds and high-strength yarns for next-generation biomedical products. These materials have been adopted by clinical partners for uses ranging from full thickness wound repair to peripheral nerve regeneration, reflecting the commercial opportunities Gurkaran helps cultivate. His focus on translating technical capability into meaningful partnerships has supported the company’s growing presence in cell biology, tissue engineering, and medical device markets.

Nish Bhat

Nish is the General Partner and Cofounder of Carbon Silicon Ventures, where he invests in companies applying engineering methodologies to biology. He is also a cofounder of the oncology company Color Health.

Jim West

Jim West III is an engineer, entrepreneur, and ecosystem builder working at the intersection of health, business, and technology to accelerate the next generation of life science tools and diagnostics startups. He currently serves as Associate Director at BioTools Innovator, where he helps design and lead programs that connect founders with strategic partners, investors, and expert mentors to bring research-enabling technologies to market faster.

Previously, Jim was co‑founder and CEO of Clara Biotech, where he led the development and commercialization of a patented exosome purification platform and helped position the company for an asset acquisition. Earlier in his career, he contributed to bringing multiple medical devices from concept through prototyping, clinical validation, and FDA clearance, including one of the first mobile medical devices to use an iPhone as a stethoscope. Jim holds master’s degrees in Biomedical Engineering Product Development from the University of Kansas and in Entrepreneurship from Nanyang Technological University in Singapore.

Carlos Ezio

Carlos Ezio is an MIT Innovators 35 Under 35 LATAM honoree and the CEO and co-founder of Criocore, a biotech company developing shelf-stable, human-relevant 3D in vitro models for drug discovery. Criocore’s goal is to provide more predictive and animal-free research tools that improve decision-making in preclinical drug development.

He previously spent six years in the Shrike Zhang Lab, a pioneering group in biofabrication and bioprinting, that is part of Harvard Medical School and Brigham and Women’s Hospital. There, he contributed to more than 30 publications, several patents, and multiple bioprinting systems. Carlos is a mechatronics engineer with expertise spanning 3D bioprinting, cryopreservation, organ-on-chip platforms, and acoustics.

Paul Russo

Paul Russo, is the Founder and CEO of K2X, a unique investment vehicle that will enable the 99% of the world with limited startup experience, to safely invest in this exciting non-correlated asset class – www.k2x.capital – with the expectation of a 2026 NYSE IPO, K2X plans to create “The ETF of Start-ups”. He was the Founder, CEO and Chairman of GEO Semi, a Leading supplier of automotive camera processors acquired by NASDAQ: “INDI”. He sits on several start-up boards and is an advisor to start-ups and VC funds. He was a board member of ATI Technologies through its acquisition by AMD and is active in the Band of Angels. Before GEO, Dr. Russo started Silicon Optix and Genesis Microchip. The latter dominated the chip market for flat computer displays and had a successful NASDAQ IPO in 1998. Prior to the above, he had several senior executive positions at GE. Prior to GE, he was at RCA Laboratories, where he helped develop the world’s first CMOS microprocessor, and the first uses of these devices in video games, auto engine control, and global communications. He has been an active angel investor for over three decades. He received his B. Eng. from McGill and his MSc and PhD in EECS from UC Berkeley. He holds 8 patents, has published extensively, and is the recipient of numerous awards, including the IEEE Centennial Medal and the Tech Pioneer Award from the World Economic Forum.

Event Sponsors:

The post Life in 3D: Investing in the Next Frontier 🗓 appeared first on 3DHeals.

Design for Additive Manufacturing (DfAM) emerged as a distinct discipline once engineers realized that “printing” parts designed for casting or machining squandered most of 3D printing’s advantages. From the 1980s through the 1990s, additive technologies such as stereolithography, fused deposition modeling, and selective laser sintering were marketed mainly for rapid prototyping, so design activity focused on speed and visualization rather than functional optimization. As industrial users in aerospace, automotive, and healthcare began adopting additive manufacturing for production parts in the 2000s and 2010s, the need to redesign components specifically around layer‑wise fabrication, support strategies, and new geometric possibilities crystallized into what is now called DfAM.

Today, DfAM is characterized by a toolbox of computational techniques—topology optimization, generative design, and architected lattice materials—implemented in specialized software from vendors such as nTop and other AM-focused platforms. These tools help engineers consolidate assemblies, lightweight structures, embed conformal cooling or fluid channels, and tailor local stiffness or porosity in ways that are impractical with conventional manufacturing. At the same time, industrial workflows increasingly integrate automated manufacturability checks, simulation of print-induced distortion, and process-aware design rules, reflecting a transition from ad hoc experimentation to more mature, engineering-driven design methodologies.

From a market perspective, DfAM grows alongside the broader additive manufacturing industry, which is projected to expand from roughly 26 billion USD in 2025 to over 125 billion USD by 2034, with design software identified as a key segment. The strongest DfAM pull comes from aerospace and defense, automotive, and industrial sectors seeking weight reduction, part consolidation, and high-performance cooling or fluid handling, followed closely by healthcare, where implants, surgical guides, and dental components benefit from patient-specific geometries and internal architectures. Additional growth areas include consumer electronics, energy, and high-value consumer products, where customized, lightweight, or ergonomically optimized designs justify the higher cost of AM and reward organizations that invest in DfAM skills and tools.

The final virtual event of the year sits within 3DHEALS’ ongoing effort to move “design for 3D technology” beyond tool-centric discussions and into questions of clinical value, scalability, and ecosystem-building. Prior and related 3DHEALS programs on “Design for Medical 3D Printing” and “Design for 3D Printed Medical Devices” emphasize topics such as patient-specific customization, digital surgical planning, and material/biomechanical considerations, and this session builds on that foundation by focusing on the next generation of design methods and software. Attendees can expect not only technical insights into computational design and constraints in 3D printing, but also a broader view of how these design philosophies are reshaping future healthcare products and workflows in “3D”.

Apply to speak or sponsor the event: info@3dheals.com

Subscribe here to receive event emails.

Speakers:

Matthew Shomper

Matthew is a visionary leader in the computational design of advanced 3D-printed medical implants, with close to 15 years of experience in engineering, research, and innovation. As an inventor, creator, and passionate leader, he has been a part of founding businesses focused on additive manufacturing and is an internationally recognized speaker on biomimicry, computational modeling, and additive manufacturing – lecturing at conferences and prestigious universities including MIT and Harvard. Matthew’s work is driven by his passion for exploring the macro and micro of biological forms, turning algorithms into functional structures for physical devices. He has pioneered the idea of a “biologically advantageous implant,” and has also spearheaded multiple public initiatives to synthesize biological structures as computational models for use in engineered products. He currently is the founder and principal consultant of Not a Robot Engineering, a co-founder of LatticeRobot, and CTO of Allumin8.

Alexander Geht

Alexander Geht is an Industrial Designer and founder of Testa-Seat, Inc., specializing in custom seating systems for children with physical disabilities. A graduate of Bezalel Academy of Art and Design and a researcher at the Technion – Israel Institute of Technology, his expertise lies in Human Centered Design and Additive Manufacturing processes, particularly Medium Scale, Pelletized Extrusion (FGF). Alexander’s praxis focuses on designing innovative and affordable assistive technology products.

Rob MacCurdy

Dr. Robert MacCurdy is an assistant professor in mechanical engineering (also by courtesy in computer science and electrical engineering) at the University of Colorado Boulder where he leads the Matter Assembly Computation Lab (MACLab). Rob is also a National Geographic Explorer. He is developing new algorithms, materials, and fabrication tools to automatically design and manufacture electromechanical systems, with a focus on robotics. He also creates automated methods to study animal behavior in the wild. Rob did his PhD work with Hod Lipson at Cornell University and his postdoctoral work at MIT with Daniela Rus. Funded by an NSF Graduate Research Fellowship and a Liebmann Fund fellowship, his doctoral work demonstrated systems capable of automatically assembling functional electromechanical devices, with the goal of printing robots that literally walk out of the printer. During this time he also created low-cost, low power, and low-mass radiofrequency tags, and developed an “inverse-GPS” tracking system based on time-of-flight measurements that use 3 orders of magnitude less energy than GPS. He holds a B.A. in Physics from Ithaca College, a B.S. in Electrical Engineering from Cornell University, and an M.S. and PhD in Mechanical Engineering from Cornell University. Prior to his Doctoral work, Dr. MacCurdy spent 10 years at the Cornell University Lab of Ornithology, where he worked as a research engineer developing remote-monitoring tools for birds and wildlife. These systems employed methods including acoustic, radiofrequency, solar-geolocation, and inertial; battery energy-density limitations led to research in multisource energy harvesting, and the first vibration energy harvesters applied to flying insects and birds. Thousands of his terrestrial and marine autonomous recording units (ARUs) have been deployed worldwide and are still in widespread use.

Nathan Shirley

Nathan Shirley is Experience and Design Lead on a cross functional team of designers, programmers and engineers leveraging computational design workflows to unlock new geometries allowing HP and its partners’ additive manufacturing businesses to thrive. His background is in industrial design, having contributed as a designer and manager on teams and projects at Tupperware and then at HP. He focuses on collaborating on teams that are pushing the boundaries of the positive impact that is possible with innovative technologies.

Joshua Steer

Joshua Steer, PhD is the Founder and CEO of Radii Devices Ltd. He completed his PhD in the Bioengineering department of the University of Southampton, UK in 2019, where he continues as a Visiting Research Follow. His prior academic research and subsequent work at Radii focuses on using software and data, such as 3D scans, to support the fitting of medical devices, and has contributed to 17 peer-reviewed journal articles. He collaborates on projects with multiple partners including the Department of Veteran Affairs X_Labs and National Health Service in the UK.

Moderator:

Dr. Jenny Chen

Dr. Jenny Chen is trained as a neuroradiologist, and founder/CEO of 3DHEALS. Her main interests include next-generation education, 3D printing in the healthcare sector, automated biology, and artificial intelligence. She is an angel investor who invests in Pitch3D companies.

The post Design for Medical 3D Technology 🗓 appeared first on 3DHeals.